Recent News

• 08.01.2026 - Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
• 06.22.2026 - Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
• 06.18.2026 - Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
• 06.18.2026 - Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
• 06.15.2026 - Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
• 06.15.2026 - Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study
• 06.08.2026 - High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
• 06.06.2026 - Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
• 05.30.2026 - SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
• 05.30.2026 - TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recent Filings

• 07.30.2026 - 144 Report of proposed sale of securities
• 07.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2026 - 8-K Current report
• 07.29.2026 - EX-99.1 EX-99.1
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities